Skip to main content
Premium Trial:

Request an Annual Quote

In Brief This Week: Kazia Therapeutics, ImaginAb, Roche, ASCO, HealthVerity, Massive Bio, AdhereTech

NEW YORK – Kazia Therapeutics said this week that a pre-specified interim analysis in a Phase II trial has shown responses in an initial group of 10 breast cancer patients receiving paxalisib. Based on this, the company will enroll 11 more patients in this arm of the trial, which is being led by the Alliance for Clinical Trials in Oncology and is studying multiple genomically guided therapies for cancers that have spread to the brain. The initial stage of the study is continuing for other drug-tumor combinations. 

ImaginAb said this week that Roche will provide its immune checkpoint inhibitor Tecentriq (atezolizumab) for ImaginAb's Phase IIb iPREDICT study. Through the ongoing study, ImaginAb's aim is to support marketing approval for its CD8 ImmunoPET agent, zirconium Zr 89 crefmirlimab berdoxam, as a biomarker to predict response to the immunotherapy in patients with melanoma, Merkel cell carcinoma, renal cell carcinoma, and non-small cell lung cancer, among other solid tumors. For its part of the supply agreement, Roche will provide ImaginAb with Tecentriq for NSCLC patients on the trial. 

The American Society of Clinical Oncology's subsidiary CancerLinQ and HealthVerity this week announced a collaborative effort to create a real-world oncology database to help advance cancer research and care. The database will use HealthVerity's Privacy-Preserving Record Linkage technology to bring together disparate datasets and maintain privacy of real-world data. The data ecosystem will include real-world, longitudinal de-identified data from patients with cancer and benign hematological conditions. CancerLinQ currently collects data from more than 100 cancer centers and community oncology practices. 

Massive Bio and AdhereTech announced this week that they are partnering to create a comprehensive technology solution to measure, analyze, and monitor precision oncology medication adherence for patients participating in clinical trials and receiving approved treatments. The companies are working with pharmaceutical companies, payors, and pharmacies to develop adherence programs based on device-generated data, which they anticipate will impart significant cost savings for the industry while improving patient access to treatments. 

Fusion Pharmaceuticals said this week it will report data from its ongoing Phase I study of its radio-immunoconjugate FPI-1434 during the first half of 2023, not in the second half of 2022 as previously anticipated. The study is evaluating FPI-1434 for patients with solid tumors expressing IGF-1R. The firm also said it expects to dose the first patients in a separate Phase I study — this one evaluating its targeted alpha therapy FPI-1966 for patients with solid tumors expressing FGFR3 — during the second half of 2022, instead of the second quarter of 2022 as previously expected. These delays are due to recruitment challenges, staffing and resource shortages, as well as administrative complications, which the company said it is addressing through mitigation plans. 

Zai Lab said this week that China's Center for Drug Evaluation and National Medical Products Administration granted two breakthrough therapy designations to repotrectinib. One is for treating patients with ROS1-positive metastatic non-small cell lung cancer who have previously received a ROS1 tyrosine kinase inhibitor and platinum-based chemotherapy. The second breakthrough designation is for repotrectinib as a treatment for patients who have received a ROS1 tyrosine kinase inhibitor without chemotherapy or immunotherapy. 

In Brief This Week is a selection of news items that may be of interest to our readers but had not previously appeared in Precision Oncology News.